These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14505091)

  • 1. Inoculation with DNA encoding the glycoprotein gp2 reduces severity of equine herpesvirus 1 infection in a mouse respiratory model.
    Learmonth GS; Love DN; Gilkerson JR; Wellington JE; Whalley JM
    Arch Virol; 2003 Sep; 148(9):1805-13. PubMed ID: 14505091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals.
    Foote CE; Love DN; Gilkerson JR; Rota J; Trevor-Jones P; Ruitenberg KM; Wellington JE; Whalley JM
    Vet Immunol Immunopathol; 2005 May; 105(1-2):47-57. PubMed ID: 15797474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equine herpesvirus 1 glycoprotein D expressed in E. coli provides partial protection against equine herpesvirus infection in mice and elicits virus-neutralizing antibodies in the horse.
    Weerasinghe CU; Learmonth GS; Gilkerson JR; Foote CE; Wellington JE; Whalley JM
    Vet Immunol Immunopathol; 2006 May; 111(1-2):59-66. PubMed ID: 16473414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inoculation of mares and very young foals with EHV-1 glycoproteins D and B reduces virus shedding following respiratory challenge with EHV-1.
    Foote CE; Raidal SL; Pecenpetelovska G; Wellington JE; Whalley JM
    Vet Immunol Immunopathol; 2006 May; 111(1-2):97-108. PubMed ID: 16504306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies.
    Soboll G; Hussey SB; Whalley JM; Allen GP; Koen MT; Santucci N; Fraser DG; Macklin MD; Swain WF; Lunn DP
    Vet Immunol Immunopathol; 2006 May; 111(1-2):81-95. PubMed ID: 16549215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
    Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC
    Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).
    Osterrieder N; Wagner R; Brandmüller C; Schmidt P; Wolf H; Kaaden OR
    Virology; 1995 Apr; 208(2):500-10. PubMed ID: 7747423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
    Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A protective effect of epidermal powder immunization in a mouse model of equine herpesvirus-1 infection.
    Kondo T; McGregor M; Chu Q; Chen D; Horimoto T; Kawaoka Y
    Virology; 2004 Jan; 318(1):414-9. PubMed ID: 14972566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combined bovine herpesvirus 1 gB-gD DNA vaccine induces immune response in mice.
    Caselli E; Boni M; Di Luca D; Salvatori D; Vita A; Cassai E
    Comp Immunol Microbiol Infect Dis; 2005 Mar; 28(2):155-66. PubMed ID: 15582691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prime-boost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus 1 in naïve and infection-primed mice.
    Ruitenberg KM; Walker C; Love DN; Wellington JE; Whalley JM
    Vaccine; 2000 Jan; 18(14):1367-73. PubMed ID: 10618534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equine herpesvirus 1 mutants devoid of glycoprotein B or M are apathogenic for mice but induce protection against challenge infection.
    Neubauer A; Beer M; Brandmüller C; Kaaden OR; Osterrieder N
    Virology; 1997 Dec; 239(1):36-45. PubMed ID: 9426444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA-mediated immunization with glycoprotein D of equine herpesvirus 1 (EHV-1) in a murine model of EHV-1 respiratory infection.
    Ruitenberg KM; Walker C; Wellington JE; Love DN; Whalley JM
    Vaccine; 1999 Jan; 17(3):237-44. PubMed ID: 9987159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The C-terminal regions of the envelope glycoprotein gp2 of equine herpesviruses 1 and 4 are antigenically distinct.
    Learmonth GS; Love DN; Wellington JE; Gilkerson JR; Whalley JM
    Arch Virol; 2002 Mar; 147(3):607-15. PubMed ID: 11958459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo characterization of equine herpesvirus type 1 (EHV-1) mutants devoid of the viral chemokine-binding glycoprotein G (gG).
    von Einem J; Smith PM; Van de Walle GR; O'Callaghan DJ; Osterrieder N
    Virology; 2007 May; 362(1):151-62. PubMed ID: 17250864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenicity and immunogenicity of equine herpesvirus type 1 mutants defective in either gI or gE gene in murine and hamster models.
    Tsujimura K; Yamanaka T; Kondo T; Fukushi H; Matsumura T
    J Vet Med Sci; 2006 Oct; 68(10):1029-38. PubMed ID: 17085880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11.
    von Einem J; Wellington J; Whalley JM; Osterrieder K; O'Callaghan DJ; Osterrieder N
    J Virol; 2004 Mar; 78(6):3003-13. PubMed ID: 14990719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the full-length form of gp2 of equine herpesvirus 1 (EHV-1) completely restores respiratory virulence to the attenuated EHV-1 strain KyA in CBA mice.
    Smith PM; Kahan SM; Rorex CB; von Einem J; Osterrieder N; O'Callaghan DJ
    J Virol; 2005 Apr; 79(8):5105-15. PubMed ID: 15795295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of intranasal immunization with recombinant glycoprotein d in pregnant BALB/c mice challenged with different strains of equine herpesvirus 1.
    Fuentealba NA; Zanuzzi CN; Scrochi MR; Sguazza GH; Bravi ME; Cid de la Paz V; Corva SG; Portiansky EL; Gimeno EJ; Barbeito CG; Galosi CM
    J Comp Pathol; 2014 Nov; 151(4):384-93. PubMed ID: 25124330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection.
    Paillot R; Ellis SA; Daly JM; Audonnet JC; Minke JM; Davis-Poynter N; Hannant D; Kydd JH
    Vaccine; 2006 Mar; 24(10):1490-500. PubMed ID: 16269205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.